Skip to main content
Clinical Trials/NCT04751448
NCT04751448
Recruiting
Not Applicable

COLON MD: Colon Cancer Longitudinal Study of the Microbial Metabolites and Dietary Factors That Influence Response to Treatment

Baylor Research Institute1 site in 1 country11 target enrollmentFebruary 1, 2021
ConditionsColon Cancer

Overview

Phase
Not Applicable
Intervention
Observational
Conditions
Colon Cancer
Sponsor
Baylor Research Institute
Enrollment
11
Locations
1
Primary Endpoint
Microbiome-Based Prediction of Chemotherapy-induced Diarrhea in Colon Cancer
Status
Recruiting
Last Updated
3 months ago

Overview

Brief Summary

The goal of this proposal is to identify how the composition of the gut microbiome and diet interact to impact chemotherapy-induced diarrhea incidence and severity.

Detailed Description

In this longitudinal observational study patients will supply samples of their gut microbiome prior to scheduled colonoscopy or surgery along with dietary intake and blood samples; the relative abundance of microbes from those samples along with dietary data will be used to predict the presence or absence and severity of chemotherapy-induced diarrhea. Microbiome and diet based predictions from blinded samples will be combined to map the diet-microbiome changes during treatment to the changes in immune markers and risk of chemotherapy-induced diarrhea.

Registry
clinicaltrials.gov
Start Date
February 1, 2021
End Date
June 1, 2026
Last Updated
3 months ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Colon cancer diagnosis
  • Age \>18 and \< or equal to
  • Ability to perform informed consent
  • FOLFOX treatment expected

Exclusion Criteria

  • Not Pregnant
  • Does not have Lynch syndrome or FAP diagnosis.
  • Inability to perform inform consent
  • inability to comply with follow up program
  • history of prior colon cancer diagnosis
  • previous treatment with antibiotics in the last month.
  • previous bowel resection.

Arms & Interventions

Observational

All patients going on study will be put in the observational grouping for blood and tissue collection with option for stool collection.

Outcomes

Primary Outcomes

Microbiome-Based Prediction of Chemotherapy-induced Diarrhea in Colon Cancer

Time Frame: 3 years

Microbiome analysis from at least 112 blinded samples will be conducted from fecal samples to determine sensitivity, specificity and accuracy (reported as percentage) of a microbiome-based predictor of chemotherapy-induced diarrhea in colon cancer.

Secondary Outcomes

  • Dietary-Based Prediction of Chemotherapy-induced Diarrhea in Colon Cancer(3 years)

Study Sites (1)

Loading locations...

Similar Trials